Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
about
Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence.Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.Recommendations for action: a community meeting in preparation for a mass-casualty opioid overdose event in Southeastern Ontario.Opioid agonist therapy.Evaluating the impact of Affordable Care Act repeal on America's opioid epidemic.Opioid substitution treatment is linked to reduced risk of death in opioid use disorder.Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic.Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.Availability of naloxone in Canadian pharmacies:a population-based survey.Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.Effect of initiating drug treatment on the risk of drug-related poisoning death and acquisitive crime among offending heroin users.Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.Buprenorphine in Neonatal Abstinence Syndrome.Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting.Extended-release injectable naltrexone for opioid use disorder: A systematic review.Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.Methadone Maintenance Treatment for Older Adults: Cost and Logistical Considerations.Opioids, Hepatitis C Virus Infection, and the Missing Vaccine.Management of opioid use disorders: a national clinical practice guideline.Suboxone: Rationale, Science, Misconceptions.Factors associated with discontinuation of methadone maintenance therapy (MMT) among persons who use alcohol in Vancouver, Canada.Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from CanadaUsing routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) StudyCurrent and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphineBuprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinionsImproving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals' attitudes and clinical practicePrimary versus secondary source of data in observational studies and heterogeneity in meta-analyses of drug effects: a survey of major medical journals
P2860
Q38605387-0BE52D6C-6D34-494B-BD02-1DEFA92B4A0AQ38695672-B91D5243-2ACA-44D1-B754-A65B3412B4E1Q41291300-49BC033E-63FB-48F7-8F08-85A476F4D394Q42333024-DB274B57-61C0-4948-B675-E160A3234689Q42351047-D3D13960-2BE4-4928-9D19-1FDF3D367865Q42356502-B262633A-BA06-4E01-8519-476BF22CC9E8Q44350939-56CA1776-795D-4558-856C-CAC1755C8743Q44350944-C6558A4C-A276-4D00-8483-26E6C45968B4Q44351156-AF309B53-F999-4B15-8D07-E61F2A27A087Q47161749-7EA38B9F-37BC-4766-A37E-EB1B64E6C48DQ47191704-7C124846-ADED-4713-AC23-7212B60C1034Q47376071-F5D46AF5-8772-428F-AD79-D496F47CECD1Q47442637-255C604C-9C93-4A61-B65C-CBC3E7923D49Q47569876-276FCBC0-E096-4ACF-A119-BFA66200635EQ47653755-878AB6D1-9395-42D0-8715-FD2973FADC00Q48096212-F4CD2E2D-FAC5-4C6A-BBCD-D22EF1B39FBCQ48111086-A7407D99-BB6F-460C-B309-C8C8CC70DFEBQ49980505-A351A5C8-EA42-491E-8BED-A5AEB9602F6EQ50062946-0BF2889B-2418-4446-824F-CC482411E9DAQ51787607-DCE95C03-C99E-4ADA-B81E-D8761EABA63AQ52315227-B8042E2E-009F-4AEE-A187-D6208878C626Q52316126-9B63A4B9-C5EE-4F3F-8A85-894826F2BA9FQ52645984-AE551BC3-0256-4BA1-AA38-73FBD232255AQ54244417-57718385-C805-406D-AD51-E44BC3F7068BQ55000232-36DBB784-E69C-4D1C-9A55-D4B38ECFC580Q56525840-BE98FA50-D666-415B-973B-0A9910D51CA6Q56888804-D1753553-0147-45EE-952C-8B0B09AC1ADBQ57816035-F79F0373-3E64-4F8B-BD07-AE0095A152B1Q58569574-63445DF5-4DC1-4DC6-ADB5-3B72EA94ECFAQ58765040-3DF3895D-D6F6-4305-AA8F-6B487D2196C3Q59128777-0126E3E8-B10C-4CED-98C2-5E50B65DDFD1
P2860
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Mortality risk during and afte ...... eta-analysis of cohort studies
@ast
Mortality risk during and afte ...... eta-analysis of cohort studies
@en
type
label
Mortality risk during and afte ...... eta-analysis of cohort studies
@ast
Mortality risk during and afte ...... eta-analysis of cohort studies
@en
prefLabel
Mortality risk during and afte ...... eta-analysis of cohort studies
@ast
Mortality risk during and afte ...... eta-analysis of cohort studies
@en
P2093
P2860
P31
P50
P921
P356
P1433
P1476
Mortality risk during and afte ...... eta-analysis of cohort studies
@en
P2093
B Iciar Indave
Lucas Wiessing
Maria J Bravo
Marica Ferri
Roberto Pastor-Barriuso
P2860
P356
10.1136/BMJ.J1550
P407
P5008
P577
2017-04-26T00:00:00Z